Health

FDA Panel Backs Moderna's mRNA Flu Vaccine for Adults Over 50

Was the FDA blocking American vaccine innovation or rightfully demanding Moderna prove its efficacy?

Published JUN 19

FDA Panel Backs Moderna's mRNA Flu Vaccine for Adults Over 50

Story

Above: Moderna logo in Warsaw, Poland, on April 9, 2025. Image credit: Jakub Porzycki/NurPhoto/Getty Images

The Facts

The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously on Thursday that the benefits of Moderna's mRNA flu vaccine, mRNA-1010, outweigh its risks for adults aged 50 and older.
The Wall Street Journal
Bloomberg
Seeking Alpha
The FDA has an action date of Aug. 5 to make a final decision on Moderna's biologics license application for mRNA-1010, also called mFlusiva. Committee recommendations are nonbinding, and the FDA is responsible for final approval.
Fox 56
PBS NewsHour
Seeking Alpha
In a phase 3 trial of over 40,000 adults aged 50 and older, the vaccine reduced flu cases by about 27% compared with a standard flu vaccine. The FDA responded favorably to the results and reported no safety concerns ahead of the meeting.
Guardian
Newsmax
The vaccine requires only two-to-three months from strain selection to vaccine rollout, down from around six months for traditional flu shots. However, FDA scientists noted the vaccine lacks data on frail older adults and those with weakened immune systems.
News Nation
NBC
The FDA had initially refused to review Moderna's application, citing the vaccine's comparison to a standard flu shot rather than existing as a high-dose version. However, the organization reversed course days later.
NPR
News Nation
PBS NewsHour
Before this, VRBPAC had not convened to review a new vaccine application in over three years. The U.S. Department of Health and Human Services reportedly canceled nearly $500 million in mRNA vaccine research funding in 2024.
NBC
NPR

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

The FDA's initial refusal to even review Moderna's mRNA flu vaccine was a regulatory disaster. Moderna ran a 43,000-person trial under an FDA-approved design, proved superiority over both standard-dose and high-dose comparators, and still got stonewalled. The EU, Canada and Australia are moving forward with reviews while American innovation gets left behind. Unpredictable regulation doesn't protect the public; it just drives vaccine development offshore.

CIDRAP

Richard Hanania on X

Narrative B

Moderna compared its mRNA flu vaccine to the weakest available flu shot, not the high-dose formulation that's been the evidence-based benchmark for older adults for nearly a decade, thereby setting an easy target. Regulatory predictability matters, but so does comparator integrity; clearing a low bar doesn't mean a product is actually better. Real innovation means proving superiority over the best available option, not the most beatable one.

Dr. Syed Haider on X